Heart failure with normal LVEF in BIOSTAT-CHF

Baumhove, L. et al. (2022) Heart failure with normal LVEF in BIOSTAT-CHF. International Journal of Cardiology, 364, pp. 85-90. (doi: 10.1016/j.ijcard.2022.05.054) (PMID:35649488)

[img] Text
274711.pdf - Published Version
Available under License Creative Commons Attribution.



Aims: Several studies have shown that heart failure (HF) drug treatment seems to benefit patients with preserved ejection fraction (HFpEF) and a left ventricular ejection fraction (LVEF) up to 55–60% but not with higher LVEF. Certain HF drugs are now indicated in patients with HFpEF and a LVEF below normal. However, not much is known about patients with a normal LVEF. Therefore, we investigated the prevalence, clinical characteristics and outcome of patients with HF and a normal LVEF. Methods and results: Normal LVEF was defined according to the Recommendations for Cardiac Chamber Quantification from the American Society of Echocardiography as a LVEF ≥62% for men and ≥ 64% for women. Preserved ejection fraction was defined as a LVEF ≥50% and reduced ejection fraction as a LVEF <50%. In the total cohort of 1568 studied patients with heart failure (mean age 73 years; 33.6% female) 57 patients (3.6%) had a normal LVEF. These patients least likely had a previous myocardial infarction (p < 0.001) or diabetes (p = 0.045), had the lowest Left Ventricular End Diastolic Diameter (p < 0.001), the highest rate of previous HF hospitalization in the last year (p = 0.015), the highest cardiac output (p < 0.001) and were most frequently women (p < 0.001). Patients with a normal LVEF had the lowest risk for the primary combined outcome of all-cause mortality and HF hospitalization. Conclusion: Only 3.6% of patients with HF had a sex-adjusted normal LVEF. Despite the sex-adjusted cut-offs they were more frequently female with less ischemic heart disease, higher cardiac output and better clinical outcomes.

Item Type:Articles
Additional Information:BIOSTAT-CHF was funded by the European Commission [FP7–242209-BIOSTAT-CHF; EudraCT 2010–020808-29].
Glasgow Author(s) Enlighten ID:Cleland, Professor John
Authors: Baumhove, L., Tromp, J., Figarska, S., van Essen, B. J., Anker, S. D., Dickstein, K., Cleland, J. G., Lang, C. C., Filippatos, G., Ng, L. L., Samani, N. J., Metra, M., van Veldhuisen, D. J., Lam, C. S.P., Voors, A. A., and van der Meer, P.
Subjects:R Medicine > R Medicine (General)
College/School:College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Robertson Centre
Journal Name:International Journal of Cardiology
ISSN (Online):1874-1754
Published Online:29 May 2022
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in International Journal of Cardiology 364: 85-90
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record